课题基金 / 基金详情

Gene therapy using lympho-epithelial Kazal-type-inhibitor (LEKTI) for head and neck cancer

Gene therapy using lympho-epithelial Kazal-type-inhibitor (LEKTI) for head and neck cancer
使用淋巴上皮 Kazal 型抑制剂 (LEKTI) 治疗头颈癌的基因治疗
批准号:
16591991
负责人:
MITSUDO Kenji
金额:
$2.11万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2004
资助国家:
日本
项目状态:
已结题
起止时间:
2004 至 2005

项目摘要

项目成果

MITSUDO Kenji的其他基金

相似基金

相关文献

中文摘要
翻译
1.将全长LEKTI cDNA亚克隆到腺病毒载体(Ad-lacZ-LEKTI)中。使用人口腔鳞状细胞系SAS、HSC-2、3、4。将2万个细胞接种到8孔玻片的每孔中。24小时后,将Ad-lacZ-LEKTI载体加入不同感染倍数(MOI)的每孔中。每孔加入X-gal溶液,测定转导效果。在24孔板上进行腺病毒载体毒性实验。24小时后,以不同的MOI将Ad-lacZ-LEKTI载体添加到每口井中。感染Ad-lacZ-LEKTI载体96 h后,用台盼蓝染色法计数活细胞数。GCV毒性实验与腺病毒实验相似。转导后的细胞用X-gal染色成蓝色。在MOI为10的情况下,所有细胞均被转导。MOI 1的转导效率几乎为20%。当MOI大于100时,Ad-lacZ-LEKTI对所有细胞系均有毒性,但当MOI小于等于10时,无明显毒性。所有细胞系对GCV的细胞毒性均为25 μg/ml以上。在24孔板的每孔中接种5万个细胞。24小时后,以不同的MOI将Ad-lacZ-LEKTI载体添加到每口井中。每孔加GCV 10 μg。用台盼蓝染色法测定给药72h后的活细胞数。当MOI为1时,可诱导60%以上的细胞死亡,当MOI为10.3时,几乎100%的癌细胞死亡。Ad-lacZ-LEKTI和GCV对口腔鳞状细胞形态学的影响。GCV给药24小时后,培养的细胞出现明显的凋亡,如染色质凝集、细胞收缩、细胞膜起泡和气球形成。少
英文摘要
1.efficacy of adenovirus vector transduction into human squamous cell lines and cytotoxicity in vitroFull length LEKTI cDNA was subcloned into adenovirus vector (Ad-lacZ-LEKTI). Human oral squamous cell lines, SAS, HSC-2, 3, 4, were used. Twenty thousand cells were inoculated into each well of an 8-well glass slide. 24 hours later, Ad-lacZ-LEKTI vectors were added to each well at varying multiplicities of infection (MOI). A solution of X-gal was added to each well, and transduction efficacy was determined. Experiments for toxicity of the adenovirus vector were performed in 24-well plates. 24 hours later, Ad-lacZ-LEKTI vectors were added to each well at varying MOI. Numbers of living cells were counted 96 hours after Ad-lacZ-LEKTI vector infection, using trypan blue dye exclusion method. Experiments for toxicity of GCV were performed similar to the experiments with adenovirus vector. The transducted cells were stained blue by X-gal staining. By 24hours after transduction, nearly 100% of … More all cells were transducted at a MOI of 10. Transduction efficacies at an MOI 1 were almost 20%. Ad-lacZ-LEKTI showed toxicity in all cell lines at an MOI of more than 100, but there was no evident toxicity at an MOI of 10 or less. The cell toxicity to GCV was evaluated in all cell lines, and found to be 25 μg/ml or more.2.effects on cancer cell death in vitroFifty thousand cells were inoculated into each well of a 24-well plate. 24 hours later, Ad-lacZ-LEKTI vectors were added to each well at varying MOI. 10 μg of GCV was added to each well. Numbers of living cells were counted 72 hours after GCV administration, using trypan blue dye exclusion method. More than 60% cell death was induced at an MOI of 1, and almost 100% cancer cell death was obtained at an MOI of 10.3.morphological changes in oral squamous cell lines treated with Ad-lacZ-LEKTI and GCVThe cells were transduced at an MOI of 10 with Ad-lacZ-LEKTI by GCV. At 24 hours after administration of GCV, the cultured cells showed signed apoptosis, such as chromatin condensation, cell shrinkage, blebbing of cell membrane, and ballooning formation. Less
期刊论文(33)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.abb.2004.12.012
发表时间: 2005-03-01
期刊: ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
影响因子: 3.9
作者: [Jayakumar, A, Kang, Y, Clayman, GL]
通讯作者: Clayman, GL
New superselective intra-arterial infusion via superficial temporary artery for oral cancer -Methods of catherization using a catheter with a curvature and P-U catheter-
新型超选择性经临时浅动脉动脉内输注治疗口腔癌 -使用弯曲导管和 P-U 导管进行导管插入的方法 -
DOI: --
发表时间: 2005
期刊: Japanese J Head Neck 31(1)
影响因子: --
作者: [Tohnai, I., Fuwa, N., Mitsudo, K., et al.]
通讯作者: et al.
浅側頭動脈よりの超選択的動注化学療法と放射線療法の連日同時併用療法-Stage III,IV口腔癌に対する術前治療-
每日同时进行颞浅动脉超选择性动脉内化疗和放疗的联合治疗 - III、IV期口腔癌的术前治疗 -
DOI: --
发表时间: 2005
期刊: 頭頸部癌 31(3)
影响因子: --
作者: [藤内 祝, 光藤 健司, 他]
通讯作者: 他
Daily concurrent chemoradiotherapy with docetaxel (DOC) and cisplatin (CDDP) using superselective intra-arterial infusion via superficial temporal artery for stage III and IV oral cancer -Possibility of organ preservation in advanced oral cancer-
每日同步放化疗采用多西他赛 (DOC) 和顺铂 (CDDP),通过颞浅动脉进行超选择性动脉内输注治疗 III 期和 IV 期口腔癌 -晚期口腔癌器官保存的可能性 -
DOI: --
发表时间:
期刊: Japanese J Head Neck 32(1)(in press)
影响因子: --
作者: [Mitsudo, K., Tohnai, I., et al.]
通讯作者: et al.
共 11 条
    Role of Caveolin-1 and IL-6 for oral cancer
    • 批准号:
      19K10338
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.58万
    • 财政年份:
      2019
    • 负责人:
      MITSUDO Kenji
    • 依托单位:
    Immunochemotherapy combined with hyperthermia for distant metastases of oral cancer using magnetic anticancer drug
    • 批准号:
      25463116
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.0万
    • 财政年份:
      2013
    • 负责人:
      MITSUDO Kenji
    • 依托单位:
    Thermochemotherapy with controlled drug delivery using a novel magnetic anti-cancer drug
    • 批准号:
      22592243
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.5万
    • 财政年份:
      2010
    • 负责人:
      MITSUDO Kenji
    • 依托单位:
    CD109 expression in the head and neck squamous cell carcinoma
    • 批准号:
      19592336
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.16万
    • 财政年份:
      2007
    • 负责人:
      MITSUDO Kenji
    • 依托单位:
    国内基金
    海外基金
    LEKTI对特应性皮炎皮肤屏障及免疫平衡的保护作用及机制研究
    • 批准号:
      81301366
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      23.0万元
    • 批准年份:
      2013
    • 负责人:
      狄正鸿
    • 依托单位: